Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026
Xenon Pharmaceuticals announced it will present detailed Phase 3 X-TOLE2 data and long-term safety results for its lead asset azetukalner at the European Epilepsy Congress in Athens. The presentations include mechanistic data supporting rational polytherapy and 48-month outcomes from the open-label extension study, highlighting the drug's potential additive effects with other antiseizure medications.
Key figures
- Phase
- Phase 3
- Participants ole
- 322
- Participants mitt
- 374
- Prior asms median
- 5
- Ole duration months
- 48
- Participants randomized
- 380
- Concomitant asms percentage
- 51.3
- Baseline seizure freq per month
- 12.75
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.